Trisodium Citrate Dihydrate (E331(iii)) CAS: 6132-04-3
Related Insights
Energy Policy Whiplash: What Wright's "Hormuz Tolls Are Off the Table" Comment Means for Chemical Trade
Recent comments from Energy Secretary Wright indicating that Hormuz tolls are no longer under consideration have introduced a new policy signal for global energy and chemical markets. Procurement and compliance teams should understand how changing policy direction can influence logistics planning, freight costs and sourcing strategies.
From Acute Shock to Structural Reset: How the Petrochemical Industry's New Normal Is Reshaping Global Sourcing
The Strait of Hormuz disruption is increasingly viewed as a long-term turning point rather than a temporary supply shock. Procurement teams are adapting sourcing strategies, supplier networks and inventory policies for a more resilient petrochemical supply chain.
China Text Helium Block and NMR Spectroscopy: What the Supply Crisis Means for Pharmaceutical Quality Control
Helium supply constraints are creating new challenges for pharmaceutical laboratories that rely on NMR spectroscopy for quality control. Procurement teams should review helium inventories, supplier allocations and long term supply resilience before laboratory operations are affected.
Taurine Supply Chain 2026: MEA Feedstock Trends and Procurement Outlook
Despite volatile monoethanolamine and ethylene oxide markets, taurine supply remains resilient. Chinese producers are offsetting feedstock pressures, offering stability for H2 2026. Supplement makers must reassess sourcing strategies to secure this dependable supply.
Heparin and Biologics Raw Materials: Supply Chain Review and Procurement Outlook for H2 2026
The biologics supply chain remained resilient through H1 2026 despite higher logistics costs. As heparin production stays concentrated and biologics demand grows, procurement teams should focus on diversification, quality assurance, and long-term supplier partnerships.
Pharmaceutical Supply Chain: H1 2026 Closing Risk Assessment
The first half of 2026 exposed major vulnerabilities in pharmaceutical supply chains. API concentration, shipping disruptions, and logistics risks are reshaping procurement strategies for H2 2026 and beyond.
Don't miss out on our updates! Subscribe to our newsletter now
We're committed to your privacy. Tradeasia uses the information you provide to us to contact you about our relevant content, products, and services. For more information, check out our privacy policy.